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Abstract
Although apoptosis (programmed cell death type I) is more frequently reported in the literature in imatinib-treated gas-
trointestinal stromal tumor (GIST) cell lines,morphological features consistentwith autophagic changes aremore often
encountered in surgical specimens of treated patients. Autophagy (programmed cell death type II) is highly regulated
by a tumor-suppressor mechanism that mainly involves the genes beclin1, PI3KIII, and bcl2. Being our material not
suitable for electron microscopy analysis (not paraformaldehyde-glutaraldehyde–fixed), we evaluated the morpholog-
ical, biochemical, and immunophenotypical profiles expected to be related to autophagy and apoptosis in a series of
surgically resected samples taken from 11 imatinib-treated patients with molecularly characterized GISTs. The sam-
ples were examined for imatinib-induced morphological changes, the presence/interactions of the autophagic-related
proteins (beclin1, PI3KIII, bcl2, and LC3-II) and the presence of apoptosis-related proteins (caspase 3, caspase 7, and
lamin A/C) by means ofWestern blot analysis and coimmunoprecipitation, complemented by immunohistochemistry.
We also studied samples of two untreated GISTs used as controls. Sampling areas with different residual cellularity
scores fromboth the imatinib-treated and untreated patients showedbiochemical and immunohistochemical evidence
of high levels of proautophagy beclin1/PI3KIII and low levels of antiautophagy beclin1/bcl2 complexes, together with
the presence of LC3-II detected by Western blot analysis, thus supporting the presence of autophagy. There was no
expression of cleaved/activated caspase 3 or 7 or cleaved lamin A/C. Our descriptive results support the idea that
GISTs activate autophagy rather than apoptosis in response to imatinib treatment and that their molecular makeup
includes fingerprints of autophagy.
Translational Oncology (2008) 1, 177–186
Introduction
There have been frequent descriptions of apoptosis in gastrointes-
tinal stromal tumor (GIST) cell lines treated with imatinib (Glivec,
Novartis, Basle, Switzerland) or receptor tyrosine kinase (RTK) inhibi-
tors [1,2], but apoptosis-associated morphological changes are only
occasionally encountered in surgical samples of GISTs.
For the last year, we have histologically examined a number of sur-
gical specimens taken after imatinib treatment in which, in addition to
previously described highly responding areas of complete cell depletion
and poorly responding areas with unchanged tumoral cellularity [3,4],
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we found areas in which the tumoral cells showed prominent intracyto-
plasmic vacuoles and relatively intact nuclei in the absence of nuclear
and cytoplasmic condensation and nuclear fragmentation. These findings,
which have previously been described at microscopic level in untreated
GISTs [5], and atmicroscopic and ultrastructural levels in imatinib-treated
GISTs [4], are consistent with autophagic rather than apoptotic changes.
Autophagy is a dynamic process in which portions of the cytoplasm
are sequestrated within a double-membrane vesicle (or autophago-
some) that fuses to the lysosome to generate what are known as auto-
lysosomes or vacuoles. The content of the autophagosome is released
into the autolysosome as a result of the action of lysosomal enzymes
and then degraded by the same enzymes [6,7]. This degradation can
promote cell survival by recycling the degraded nucleotides, amino
acids, and fatty acids that maintain energy production or can promote
cell death as a result of self-cannibalization [8].
The main difference between autophagy and apoptosis is that the
latter invariably leads to cell death, whereas the former may contribute
to cell survival or death depending on the threshold level: high levels
of autophagy promote cell death [9].
Autophagy is known as programmed cell death type II (apoptosis
is programmed cell death type I) and is highly regulated by means of a
tumor-suppressor mechanism [10]. It is molecularly controlled mainly
by constitutively expressed autophagy-related genes: beclin1 (the ma-
jor player) and PI3K class I (PI3KI ) and class III (PI3KIII ). Beclin1 is a
haploinsufficient tumor-suppressor that is not required for apoptosis
but is necessary for autophagy [11,12]. PI3KI and PI3KIII have oppo-
site effects on autophagy, which is inhibited by the activation of PI3KI
but initiated by PI3KIII forming a complex with beclin1 [13,14].
Beclin1 can also bind bcl2, which, in addition to being an important
regulator of apoptosis, may inhibit autophagy by directly interacting
with beclin1. Growing evidence suggests that the beclin1/bcl2 complex
may act as a rheostat ensuring the threshold for cell homeostasis or
cell death depending on the presence of a beclin1 function that is re-
spectively checked or unchecked by bcl2 [15,16]. Another widely ac-
cepted molecular autophagic marker is the posttranslational modified
microtubule-associated protein light chain 3 (LC3-II), which is de-
rived from cytosolic LC3-I because of lipidization during autophagy.
LC3-II closely binds to autophagosomes, and its amount closely cor-
relates with the number of autophagosomes [17]. Interestingly, the
regulatory pathway of autophagy shares a number of molecules with
the oncogenic pathways activated by RTKs, such as the PI3KI/AKT/
mTOR and RAS/RAF/MEK1/2/MAPKs pathways. The first inhibits
autophagy and activates cancer growth, whereas the second can pro-
mote autophagy and cancer growth [18]. The activated RTKs in GISTs
are KITand PDGFRA, together with their downstream effectors (PI3KI/
AKT and MAPKs), and imatinib is their main starvation inducer.
Within the framework of this quite new scenario, we evaluated the
morphological, biochemical, and immunophenotypical profiles expected
to be related to autophagy and apoptosis in a series of molecularly char-
acterized GISTs taken from surgically resected imatinib-treated patients.
The results showed no signs of apoptosis but a number of indirect mark-
ers of autophagy, which is in keeping with clinical observations suggest-
ing prompt tumoral regrowth when imatinib is discontinued.
Materials and Methods
Patients and Materials
Table 1 summarizes the details. The case material consisted of 13
surgical specimens: 6 from a previous study of imatinib-treated ad-
vanced GISTs (numbers in bold) [3,19]; 5 from patients undergoing
a neoadjuvant GIST protocol (numbers in italics); and 2 (used as con-
trols) from untreated patients. Paraffin-embedded and frozen material
was available for each patient. The GIST diagnosis was confirmed on
paraffin-embedded material by means of immunohistochemical (IHC)
analyses using antibodies against CD117, CD34, PDGFRA, desmin,
actin, andMib-1, as previously described [3,20].Written informed con-
sent was obtained from all of the patients.
Clinical findings Tumor location and TNM status (primary [P], re-
currence [R], andmetastasis [M]) and the dose and duration of imatinib
treatment applied to advanced (number in bold) and neoadjuvant
(number in italic) cases are shown in Table 1. The neoadjuvant treat-
ment protocol was generally shorter (approximately 12 months) than
that used for surgically treated advanced cases. Imatinib treatment was
discontinued 12 to 36 hours before the surgical procedures in all cases.
Nine patients were judged to be clinical responders (r) and two clinical
progressors (p). The two clinical progressors belonged to advanced cases
and showedmicroscopically both highmitotic index andMib1 labeling,
and theGIST corresponding to case no. 11, harbored a secondarymuta-
tion.Clinically, the response was assessed bymeans of both the Response
Evaluation Criteria in Solid Tumors and the Choi criteria [21,22].
Gene mutation analysis The samples of the patients that had not
been previously characterized were analyzed for c-Kit and PDGFRA
gene mutations as described by Miselli et al. [3]. Among c-kit muta-
tions, one secondary mutation at exon 17, known to be related to
imatinib resistance, was observed. No PDGFRA gene mutations were
detected. The molecular findings in all of the patients are shown
in Table 1.
Morphology
Histological response assessed on paraffin-embedded surgical
specimens. One hundred five samples/nodules from the 11 surgical
specimens were assessed for tumor response based on residual cellu-
larity, the mitotic index, and Ki-67 labeling, and the results were aver-
aged for each case. Residual cellularity was scored as follows: a, <10%;
b, 10% to 50%; c, 50% to 90%; and d, >90%. Averaging yields the
following scores: high responders, 0 to <50% residual viable tumoral
cells with nomitosis and no obvious Ki-67 immunostaining; moderate
responders, >50% to 90% tumoral cells, no mitosis, and Ki-67 im-
munostaining in 0 to <10% of cells; low responders, >50% to 90%
tumoral cells, mitotic index >10/50 high-power fields, Ki-67 immu-
nostaining in 20% to 30% or >30% of cells.
Histological response assessed on frozen material. The 11 fro-
zen specimens obtained from the 11 treated patients (one sample for
each case) were analyzed to assess the response to imatinib based on
the morphological criterion of residual cellularity (scored as described
above). For details, see Table 1.
Biochemical Analysis
Positive controls The NIH3T3 (American Type Culture Collec-
tion, Manassas, VA), HeLa (kindly provided by Dr. A. Greco), and
HEK293 cell lines (kindly provided by Dr. A. Greco) were used as
positive controls for the beclin1, PI3KIII, bcl2, and LC3-II blots; the
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staurosporine-treated HeLa cell line was used as a positive control for
the caspase 3, caspase 7, lamin A/C, and LC3-II blots.
Protein extraction, Western blot analysis, and coimmunoprecip-
itation The cytoplasmic and nuclear proteins were extracted as
previously described [24,25]. The protein extracts underwent elec-
trophoresis and immunoblot analysis using standard protocols and
30 μg of cytoplasmic or nuclear protein lysates per sample.
The antibodies tested by means of immunoblot analysis included
rabbit polyclonal anti-beclin1 (H-300: sc-11427; Santa Cruz Bio-
technology, Santa Cruz, CA) diluted 1:200; rabbit polyclonal anti-
PI3KIII (anti-Vps34, 38-2100; Zymed Laboratories Invitrogen
immunodetection, South San Francisco, CA) diluted 1 μg/ml; mouse
monoclonal anti-bcl2 (clone 124 code: M0887; DakoCytomation,
Glostrup, Denmark) diluted 1:200; rabbit–polyclonal anti–LC3-II
(LC3B, #2775; Cell Signaling Technology, Danvers, MA) diluted
1:1000; rabbit polyclonal anti–caspase 3 (#9662; Cell Signaling
Technology) diluted 1:500; rabbit polyclonal anti–cleaved-caspase 7
(Asp 198, #9491; Cell Signaling Technology) diluted 1:1000; rabbit
polyclonal anti–lamin A/C (#2032; Cell Signaling Technology) diluted
1:1000; and antiactin (A2066; Sigma, St. Louis, MO) diluted 1:5000.
For the coimmunoprecipitation experiments, 1 mg of protein ly-
sate per sample was immunoprecipitated by means of incubation
with 5 μl of rabbit polyclonal anti-beclin1 antibody (sc-11427; Santa
Cruz Biotechnology) and protein A Sepharose (Sigma). Immunoblot
analysis was performed using the same anti-beclin1 antibody, and the
filters were then stripped and incubated with anti-PI3KIII and anti-
bcl2 antibodies. The secondary antibodies included anti-rabbit (Sigma),
anti-mouse (Sigma), and protein A-HRP (Amersham Biosciences,
Piscataway, NJ) used at the recommended dilutions. After hybridiza-
tion with the secondary antibody, the blots were incubated with ECL
Western Blotting Detection Reagents (Amersham Biosciences) and ex-
posed onto ECL Hyperfilm (Amersham Biosciences).
Immunohistochemistry
The IHC analyses were made using 2 μm of the formalin-fixed
and paraffin-embedded samples of those surgical specimens whose
residual cellularity was comparable with that of the corresponding
frozen sample (see letters in bold in Table 1) and the UltraVision LP
Large Volume Detection System HRP Polymer (code TL-125-HL;
Lab Vision Corporation, Newmarket, UK) with the following primary
antibodies (all except anti-PI3KIII previously used in the biochemical
analysis): anti-beclin1 diluted 1:100, anti-PI3KIII [PI3KC3 antibody
(N-term) AP8014a; Abgent, San Diego, CA] diluted 1:50, and anti-
bcl2 diluted 1:500 to investigate the expression of autophagy-related
proteins; and anti–cleaved caspase 3 (Asp175, #9661; Cell Signaling
Technology) diluted 1:600, anti–lamin A/C diluted 1:100, and anti–
cleaved lamin A/C (Small Subunit, #2035; Cell Signaling Technology)
diluted 1:50 to investigate the presence of apoptosis. Peroxidases were
blocked in 3% H2O2 (Sigma) for 10 minutes. The antigens were re-
trieved in an autoclave at 95°C in 10 mM citrate buffer, pH 6, for
15 minutes (PI3KIII, cleaved caspase 3, lamin A/C, and cleaved lamin
A/C) or 30 minutes (beclin1), or in 5 mM citrate buffer, pH 6, for
6 minutes (bcl2). The primary antibodies were incubated as follows:
anti-beclin1 and anti-bcl2 for 1 hour at 25°C; anti-PI3KIII overnight at
25°C; and anti–cleaved caspase 3, anti–lamin A/C, and anti–cleaved
lamin A/C overnight at 4°C. The reactions were developed using
Figure 1. Post–imatinib morphological regression changes ranging from an acellular area characterized by the presence of eosinophilic
proteinaceous matrix (A) sometime intermingled with ectatic vessels surrounded by hyaline sclerosis (B) and clusters of viable tumoral
cells with prominent perinuclear vacuolization and relatively intact nuclei (C) in the absence of nuclear or cytoplasmic condensation and
fragmentation (D, insert). The multivacuolated tumoral cells showed a null immunophenotype with cleaved lamin A/C antibody, with
negative lymphocytes (bottom right, dotted area) as an in-built control. (E) Area of more regressive changes in which the tumoral cells
have lost their morphology and acquired histiocytic features.
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3,3′-diaminobenzidine (DakoCytomation) as chromogen for 10 min-
utes at room temperature.
Results
Pathology
Regression changes in treated patients We analyzed b samples
(with residual cell component of 10-50%) and c samples (with a resid-
ual cell component of 50-90%) in which acellular areas characterized
by the presence of an eosinophilic proteinaceous matrix variously de-
fined as myxoid, collagenous, or hyaline [5,26], and often associated
with ectatic vessels surrounded by hyaline sclerosis (called a: residual
cell component, <10%), were intermixed with clusters of viable tu-
moral cells with prominent perinuclear vacuolization and relatively in-
tact nuclei in the absence of nuclear or cytoplasmic condensation and
fragmentation: i.e., devoid of apoptosis hallmarks. These multivacuo-
lated tumoral cells showed nuclear immunostaining with full-length
lamin A/C antibody and a null immunophenotype with cleaved lamin
A/C antibody. Scattered lymphocytes negative for lamin A/C and posi-
tive for CD3 (data not shown) were also present. Areas of more regres-
sive changes were found in which the tumoral cells had lost their
morphology and acquired histiocytic features (corresponding to a sam-
ples; Figure 1). We also analyzed d samples (residual cell component,
>90%) and two samples from untreated patients.
Biochemical Analyses
All of the samples were analyzed by means of Western blot (WB)
analysis to assess the expression of the beclin1, PI3KIII, bcl2, and
LC3-II proteins. The biochemical data are shown in Table 2, which
also shows the data regarding clinical and histological responses (on
both fixed and frozen material), details of which are reported in
Table 1; some representative cases are shown in Figure 2, A and B.
Beclin1 and PI3KIII expression Similar 2+ expression of beclin1
and PI3KIII was observed in the untreated cases and the treated low
responders. In the moderate and high responders, beclin1 expression
corresponded to respectively 2+ and 1+, whereas, although retaining the
same trend throughout the groups, PI3KIII was less expressed, ranging
from weakly positive (+w) to 1+. In no. 7, a sample in which residual
cellularity was very low, beclin1 was positive but PI3KIII-negative.
Bcl2 expression The expression of bcl2 in the untreated cases and
low responders was more heterogeneous than the two autophagy-
related markers described above, and this tendency was confirmed
by IHC analysis (data shown later in the Table 2). This finding is
in keeping with the observed variability in bcl2 expression in primary
tumors [27] and that found in the two unselected control GISTs, in
which bcl2 expression was 1+ and 2+ (comparing the expressions of
tumoral cells and in-built lymphocytes). On the contrary, in the
moderate and high responders, the expression profile of bcl2 was
the same as that of PI3KIII.
Figure 2. Autophagy-related protein expression in imatinib-treated
and untreated GISTs (A and B) and their interactions in the auto-
phagic process (C). (A) Western blot analyses using anti-PI3KIII, anti-
beclin1 and anti-bcl2 antibodies: the arrows indicate the bands
corresponding to the three proteins and their molecular weights.
The anti-actin antibody was used as a control for protein loading
and amount, corresponding to the residual cellularity of each ana-
lyzed sample. Lanes C+: positive controls (HeLa and HEK293 cell
lines). The numbers correspond to the cases listed in Table 1, and
letters correspond to the histological responses of the samples
(residual tumoral cells: b, 10-50%; c, 50-90%; d, >90%); un: un-
treated patient. (B) Western blot analyses using anti-LC3B antibody:
the arrows indicate the bands corresponding to LC3-I and LC3-II
and their molecular weights. The anti-actin antibody was used as
control for protein loading and amount, corresponding to the resid-
ual cellularity of each sample. Lanes C+: positive controls [HeLa,
staurosporine-treated HeLa (S-t HeLa), and HEK293 cell lines]. The
numbers correspond to the cases listed in Table 1, and letters cor-
respond to the histological responses of the samples (residual tu-
moral cells: b, 10-50%; c, 50-90%; d, >90%); un: untreated patient.
(C) Coimmunoprecipitation experiments. Total protein extract (1 mg)
from each sample was immunoprecipitated using anti-beclin1 anti-
body, run on gel, and blotted with the indicated antibodies: the ar-
rows indicate the bands corresponding to the three investigated
proteins, and their molecular weights. Lanes C+: positive controls
(HEK293 andHeLa cell lines forWBPI3KIII and beclin1;HeLa cell line
alone for WB bcl2). The numbers correspond to the cases listed in
Table 1, and the letters correspond to the histological responses of
the samples (residual tumoral cells: b, 10-50%; c, 50-90%; d,
>90%); un: untreated patient.
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LC3-II expression Excluding the two negative cases among the
high responders, the results were similar to those relating to PI3KIII
in 9 of the 11 treated and untreated cases, in keeping with the role of
PI3KIII in initiating autophagy and that of LC3-II in a later phase.
Furthermore, as the amount of LC3-II correlated well with the num-
ber of autophagosomes, the absence of LC3-II in the presence of
PI3KIII is consistent with their degradation in the two most regres-
sing samples (b).
Coimmunoprecipitation experiments to confirm the presence of
autophagy The interactions between beclin1/PI3KIII and beclin1/
bcl2 were assessed by means of coimmunoprecipitation experiments.
The results are shown in Table 2 and some cases in Figure 2C .
Beclin1. All of the protein extracts from each sample immuno-
precipitated using an antibody specific for beclin1 protein showed a
corresponding 60-kDa band after membrane incubation. The inten-
sity of the band (1+, 2+) varied from sample to sample in accordance
with the expression revealed by the WB experiments and was in line
with residual cellularity.
Beclin1/PI3KIII interaction. With the exception of one case
(no. 7), all of the evaluable samples coexpressed beclin1 and PI3KIII.
Given the differences in residual cellularity between the high/moderate
and low responders/untreated cases, coexpression was definitely greater
in the former.
Beclin1/bcl2 interaction. The range of beclin1 and bcl2 co-
expression (from +w to 1+) was smaller than that of beclin1 and
PI3KIII. Given also that the expression levels of PI3KIII and bcl2
were similar in the high and moderate responders, these findings sup-
port the view that a small amount of bcl2 protein directly interacts
with beclin1.
Taken together, the high levels of proautophagy beclin1/PI3KIII
complexes and low levels of antiautophagy beclin1/bcl2 complexes
are consistent with the presence of autophagy.
Expression of apoptosis-related proteins All of the samples were
analyzed by means of WB experiments to assess the expression of
full-length and cleaved caspase 3, cleaved caspase 7, and full-length
and cleaved lamin A/C proteins. The results are shown in Table 2.
Caspase 3 and lamin A/C were only present as full-length proteins
in all of the treated patients (regardless of their residual cellularity or
clinical/histological group) and the untreated patients. The caspase 7
antibody, which only recognizes the large fragment of the enzyme
resulting from apoptosis-induced cleavage, was not found in any of
the treated or untreated cases (Figure 3, which shows some represen-
tative cases).
Taken together, the results show the absence of apoptotic hall-
marks in all of the patients.
Confirmatory IHC Analyses
Expression of autophagy-related proteins To confirm the expres-
sion of autophagy-related proteins, sections obtained from paraffin-
embedded samples whose residual cellularity was comparable with
that of the corresponding frozen samples were screened for beclin1,
PI3KIII, and bcl2.
The imatinib-treated and untreated cases all showed cytoplasmic
reactivity for beclin1, PI3KIII, and bcl2. The results of the IHC
analysis are shown in Table 2 and Figure 4A.
Expression of apoptosis-related proteins To investigate the pres-
ence of apoptosis, further sections from the same samples were incu-
bated with cleaved caspase 3 and full-length and cleaved lamin A/C
antibodies. All of the imatinib-treated and untreated cases were
positive for full-length lamin A/C with nuclear reactivity, whereas
no immunostaining was observed for cleaved/activated caspase 3 or
cleaved lamin A/C (Figure 4B). The results of the IHC analysis are
shown in Table 2.
The finding of autophagy-related protein expression in all of the
treated and untreated samples in the absence of apoptosis-related
protein expression supports the idea that autophagy is part of the
molecular profile of GISTs.
Comparison of Biochemical and IHC Results
Given that immunoreactivity relates to individual cells and the
biochemical data to residual cellularity (i.e., the actin value), the bio-
chemical and IHC results concerning the expression of autophagy-
and apoptosis-related proteins correlated in both the treated and
untreated patients.
Discussion
Our morphological, biochemical, and immunophenotypical re-
sults provide a strong indirect evidence that imatinib-induced tumoral
Figure 3. Apoptosis-related protein expression in imatinib-treated
and untreated GISTs. The WB analyses were performed using anti-
caspase 3, anti–cleaved caspase 7, and anti–lamin A/C antibodies:
the arrows indicate the bands corresponding to the expression of
the three proteins and their molecular weights. In the case of cas-
pase 3 and lamin A/C, the bands corresponding to both the full-
length and cleaved/activated proteins are indicated. The anti-actin
antibody was used as a control for protein loading. Lanes C+: posi-
tive controls [HeLa and staurosporine-treated HeLa (S-t HeLa) cell
lines]. The numbers correspond to the cases listed in Table 1, and
the letters correspond to the histological response of the samples
(residual tumoral cells: b, 10-50%; c, 50-90%; d, >90%); un: un-
treated patient.
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regression in patients with posttreatment surgically resected GISTs is
sustained by autophagy rather than apoptosis.
It has recently been reported that, in addition to inhibiting RTK
phosphorylation and inducing cell cycle arrest, imatinib activates auto-
phagy [28]. Autophagy is a dynamic rearrangement of the subcellular
membranes that leads to autophagic bodies (corresponding to vacuoles
at histological level), which may contribute to tumoral death by means
of self-cannibalization, although, unlike apoptosis (which invariably
leads to cell death), it may also contribute to cell survival [9]. Mainly
investigated on cell lines and by means of electron microscopy [29], the
only assay able to demonstrate autophagosomes, autophagy is regulated
by a tumor-suppressor mechanism in which the major players are the
activating beclin1/PI3KIII complex, the suppressing beclin1/bcl2 com-
plex [8], and the presence of LC3-II strictly bound to autophagosomes.
In line with this, we found that most of the samples in our high, mod-
erate, and low histological response groups expressed beclin1/PI3KIII,
beclin1/bcl2, and LC3-II in the absence of any morphological, IHC, or
biochemical marker of apoptosis.
There was a close correlation between the expression of autophagic
gene products and the residual tumoral cellularity, a finding that is un-
derlined by the immunophenotypical profile (Figure 1) and in keeping
with the assumption that autophagy represents a single cell’s adap-
tation to starvation [30]. There was in fact a trend toward a threshold
decrease in the autophagy pathway in the a and b samples, although b
samples showed a definite relative excess of autophagic markers, such
as excess beclin1 in beclin1/bcl2 complexes in the presence of beclin1/
PI3KIII complexes. This is in line with the idea that ourmorphological
and biochemical findings may represent the end of a phenomenon in
which the rapid nonphysiological up-regulation of autophagy trig-
gered by imatinib-induced receptor starvation is in part extinguished.
As PI3KIII is responsible for initiating autophagy by forming com-
plexeswith beclin1 andLC3-II expression corresponds to autophagosome
Figure 4. Immunohistochemical analysis of two imatinib-treated GISTs, showing residual cellularity b (case 2) and c (case 5). (A) Expres-
sion of autophagy-related proteins. Both cases show cytoplasm decoration for PI3KIII, beclin1, and bcl2. (B) Expression of apoptosis-
related proteins. Both cases show nuclear immunoreactivity for full-length lamin A/C and no immunostaining for cleaved/activated
caspase 3 or cleaved lamin A/C.
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formation, the absence of LC3-II protein in two b samples is not unex-
pected: it is conceivable that most of autophagosomes in high responders
(b) have already been digested by lysosomal enzymes and that, in moder-
ate responders (c), autophagy is still at such an early stage that tumoral
cells can retain their vitality.
The low bcl2 expression in beclin1/bcl2 complexes in the post-
treatment regressing tumors is in keeping with the idea that the
down-regulation of bcl2 induces autophagic cell death [31] and does
not conflict with the view that GISTs with high bcl2 levels are more sus-
ceptible to a KIT inhibitor such as imatinib [27]. However, as approxi-
mately 70% of GISTs express bcl2, and our series did not include any
matched pretreatment and posttreatment samples, we can only say that
bcl2 contributes to regulating the process of autophagy and that the bcl2
threshold in b and c samples is consistent with cell death.
The fact that the autophagy gene profile in the low responding
group did not substantially differ from that in the untreated cases
strongly suggests that autophagy is not acquired, but part of the mo-
lecular profile of GISTs, and that imatinib-treated GIST cells trigger
the same machinery as that used to control cell growth. This assump-
tion, which is also suggested by the marked vacuolization reported to
be a notable histological feature in GIST [32,33], is in line with the
recently underlined close relationship between the type of cell survival/
death used by each tumor type, and its response to drug treatment [34].
Remarkably, we did not observe any morphological changes cor-
responding to apoptosis, a finding that was corroborated by the nega-
tive results of the biochemical and IHC experiments using caspase 3,
caspase 7, and lamin A/C antibodies. This absence of apoptosis only
apparently conflicts with in vitro experiments because the cell model
does not work under nutrient starvation conditions [1,2] and cell
lines are treated with imatinib for only a short time. Furthermore,
fingerprints of autophagy (but not apoptosis) were also found in
the GIST specimens taken from two untreated patients. In this con-
text, it is worth noting that although it inhibits KIT activation, ima-
tinib may fail to induce apoptosis in GIST882 cell lines [35,36], thus
suggesting that its antiproliferative effect may be mediated by cell
cycle arrest rather than apoptosis. This is in keeping with clinical ob-
servations in which the rapid switching off of tumoral TK activity is
not paralleled by a decrease in tumor size: also known as “tumor dor-
mancy,” this fits well with the metabolic characteristics of autophagy.
Given the pleiotropic role of autophagy, and the evidence that it
and GISTs share a number of RTK pathways, our findings suggest
various considerations. First, as autophagy seems to exist in both un-
treated and treated GISTs, it is conceivable that it may contribute to
controlling tumoral cell growth in untreated cases, while being the
result of a specific stress response to the imatinib-induced starvation
of RTK activation in treated GISTs.
Second, the pleiotropism of autophagy may explain the wide spec-
trum of posttreatment changes which, depending on the threshold of
nutrient starvation and the recognized clonal composition of GISTs,
may range from areas showing a complete loss of cellularity or very few
scattered and regressing residual cells, to clusters of still viable multi-
vacuolated tumoral cells and clusters of tumoral cells lacking posttreat-
ment features in nonresponsive areas.
Third, the pleiotropic role of autophagy may explain the prompt
tumoral regrowth that occurs when the treatment is discontinued: re-
moving the starvation block (imatinib) may allow the still viable multi-
vacuolated tumoral cells to resume functioning.
Finally, in relation to the activation of RTK pathways, the evi-
dence that rapamycin may overcome resistance to imatinib once
again strongly supports the involvement of autophagy in GISTs:
mTOR is a downstream intermediate of the PI3KI/AKT pathway,
and rapamycin can eliminate its inhibitory effects and thus favor au-
tophagy [37]. In this light, it is interesting to note that we have re-
cently investigated RTK downstream signaling in 15 treated and 5
untreated GISTs (partially overlapping the present series; manuscript
submitted) and found MAPK cascade activation, which is known to
promote autophagy [38,39].
In conclusion, although the unavailability of paraformaldehyde-
glutaraldehyde–fixed material made it impossible to use electron mi-
croscopic assay and a direct demonstration of autophagy could not be
provided, through the analysis of surgical specimens, we provided a
substantial number of descriptive observational data which, together
with clinical and imaging evidence, strongly suggest that autophagy
rather than apoptosis seems to be activated in GISTs in response to
imatinib treatment. Further investigations, including the analysis of
imatinib-treated normal tissue, and focusing on mechanistic insights
into the role of autophagy in imatinib response through in vitro as-
says are needed to confirm these preliminary descriptive data.
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